Adult acute erythroleukemia: An analysis of 91 patients treated at a single institution

F. P.S. Santos, S. Faderl, G. Garcia-Manero, C. Koller, M. Beran, S. O'Brien, S. Pierce, E. J. Freireich, X. Huang, G. Borthakur, C. Bueso-Ramos, M. De Lima, M. Keating, J. Cortes, H. Kantarjian, F. Ravandi

Research output: Contribution to journalArticle

Abstract

Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC). Forty-five patients (50%) had a history of myelodysplatic syndrome (MDS), compared with 41% in our control group (patients with other AML subtypes) (P=0.08). Poor-risk cytogenetics were more common in patients with AML-M6 (61% versus 38%, P=0.001). Complete remission rates were 62% for patients with AML-M6, comparing with 58% for the control group (P=0.35). Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05). Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.

Original languageEnglish (US)
Pages (from-to)2275-2280
Number of pages6
JournalLeukemia
Volume23
Issue number12
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Leukemia, Erythroblastic, Acute
Acute Myeloid Leukemia
Control Groups
Disease-Free Survival
Acute erythroleukemia
Survival
Karyotype
Cytogenetics
Multivariate Analysis

Keywords

  • acute erythroleukemia
  • clinical features
  • prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Santos, F. P. S., Faderl, S., Garcia-Manero, G., Koller, C., Beran, M., O'Brien, S., ... Ravandi, F. (2009). Adult acute erythroleukemia: An analysis of 91 patients treated at a single institution. Leukemia, 23(12), 2275-2280. https://doi.org/10.1038/leu.2009.181

Adult acute erythroleukemia : An analysis of 91 patients treated at a single institution. / Santos, F. P.S.; Faderl, S.; Garcia-Manero, G.; Koller, C.; Beran, M.; O'Brien, S.; Pierce, S.; Freireich, E. J.; Huang, X.; Borthakur, G.; Bueso-Ramos, C.; De Lima, M.; Keating, M.; Cortes, J.; Kantarjian, H.; Ravandi, F.

In: Leukemia, Vol. 23, No. 12, 01.12.2009, p. 2275-2280.

Research output: Contribution to journalArticle

Santos, FPS, Faderl, S, Garcia-Manero, G, Koller, C, Beran, M, O'Brien, S, Pierce, S, Freireich, EJ, Huang, X, Borthakur, G, Bueso-Ramos, C, De Lima, M, Keating, M, Cortes, J, Kantarjian, H & Ravandi, F 2009, 'Adult acute erythroleukemia: An analysis of 91 patients treated at a single institution', Leukemia, vol. 23, no. 12, pp. 2275-2280. https://doi.org/10.1038/leu.2009.181
Santos FPS, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S et al. Adult acute erythroleukemia: An analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec 1;23(12):2275-2280. https://doi.org/10.1038/leu.2009.181
Santos, F. P.S. ; Faderl, S. ; Garcia-Manero, G. ; Koller, C. ; Beran, M. ; O'Brien, S. ; Pierce, S. ; Freireich, E. J. ; Huang, X. ; Borthakur, G. ; Bueso-Ramos, C. ; De Lima, M. ; Keating, M. ; Cortes, J. ; Kantarjian, H. ; Ravandi, F. / Adult acute erythroleukemia : An analysis of 91 patients treated at a single institution. In: Leukemia. 2009 ; Vol. 23, No. 12. pp. 2275-2280.
@article{e154ce61a71e4d87a664b9e541abe8c6,
title = "Adult acute erythroleukemia: An analysis of 91 patients treated at a single institution",
abstract = "Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC). Forty-five patients (50{\%}) had a history of myelodysplatic syndrome (MDS), compared with 41{\%} in our control group (patients with other AML subtypes) (P=0.08). Poor-risk cytogenetics were more common in patients with AML-M6 (61{\%} versus 38{\%}, P=0.001). Complete remission rates were 62{\%} for patients with AML-M6, comparing with 58{\%} for the control group (P=0.35). Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05). Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.",
keywords = "acute erythroleukemia, clinical features, prognosis",
author = "Santos, {F. P.S.} and S. Faderl and G. Garcia-Manero and C. Koller and M. Beran and S. O'Brien and S. Pierce and Freireich, {E. J.} and X. Huang and G. Borthakur and C. Bueso-Ramos and {De Lima}, M. and M. Keating and J. Cortes and H. Kantarjian and F. Ravandi",
year = "2009",
month = "12",
day = "1",
doi = "10.1038/leu.2009.181",
language = "English (US)",
volume = "23",
pages = "2275--2280",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Adult acute erythroleukemia

T2 - An analysis of 91 patients treated at a single institution

AU - Santos, F. P.S.

AU - Faderl, S.

AU - Garcia-Manero, G.

AU - Koller, C.

AU - Beran, M.

AU - O'Brien, S.

AU - Pierce, S.

AU - Freireich, E. J.

AU - Huang, X.

AU - Borthakur, G.

AU - Bueso-Ramos, C.

AU - De Lima, M.

AU - Keating, M.

AU - Cortes, J.

AU - Kantarjian, H.

AU - Ravandi, F.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC). Forty-five patients (50%) had a history of myelodysplatic syndrome (MDS), compared with 41% in our control group (patients with other AML subtypes) (P=0.08). Poor-risk cytogenetics were more common in patients with AML-M6 (61% versus 38%, P=0.001). Complete remission rates were 62% for patients with AML-M6, comparing with 58% for the control group (P=0.35). Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05). Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.

AB - Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC). Forty-five patients (50%) had a history of myelodysplatic syndrome (MDS), compared with 41% in our control group (patients with other AML subtypes) (P=0.08). Poor-risk cytogenetics were more common in patients with AML-M6 (61% versus 38%, P=0.001). Complete remission rates were 62% for patients with AML-M6, comparing with 58% for the control group (P=0.35). Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05). Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.

KW - acute erythroleukemia

KW - clinical features

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=74049153757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049153757&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.181

DO - 10.1038/leu.2009.181

M3 - Article

C2 - 19741728

AN - SCOPUS:74049153757

VL - 23

SP - 2275

EP - 2280

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -